Sept. 14, 2018
Publication of financial statements as of June 30, 2018
Welcome to Innate Pharma
Scroll
About Innate Pharma
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients
Latest news
Innate Pharma reports first half 2018 financial results and business update
September 14, 2018
Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi®) in solid tumors
September 12, 2018
Innate Pharma announces data presentations at upcoming scientific meetings
September 10, 2018
Upcoming events
EORTC CLTF 2018 Meeting Cutaneous Lymphoma | St Gallen, Switzerland
September 27, 2018 to September 29, 2018
ESMO 2018 Congress | Munich, Germany
October 19, 2018 to October 23, 2018
SITC Annual Meeting 2018 | Washington DC, USA
November 7, 2018 to November 11, 2018